BiotechTube
Home/Pipeline/TREX1

TREX1

Oncology (unspecified)

PreclinicalOut-licensed

Key Facts

Indication
Oncology (unspecified)
Phase
Preclinical
Status
Out-licensed
Company
Sprint Bioscience

About Sprint Bioscience

Sprint Bioscience is a preclinical-stage biotech company leveraging fragment-based drug discovery to develop novel oncology therapeutics. Its capital-efficient business model centers on advancing programs to a preclinical proof-of-concept before out-licensing them to larger pharma partners, as demonstrated by a major deal with Gilead Sciences. The company is expanding its pipeline into metabolic/inflammatory diseases through collaborations, aiming to address high-need areas with significant commercial potential.

View full company profile

Therapeutic Areas

OncologyMetabolic DiseasesInflammatory Diseases

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
ARX305NovoCodex BiopharmaceuticalsPhase 1
ARX788NovoCodex BiopharmaceuticalsPhase 1
Cancer Immunotherapy NanotherapeuticFlashpoint TherapeuticsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
GRC 65327Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a